Stable suppression of HER-2 gene expression using siRNA increases the lysis of human ovarian carcinoma cells mediated by NK-92 cell line

Oncology Reports

Volumn 20, Issue 6, 2008, Pages 1425-1431

  Zhou, Ying ^a,b   Cheng, Zhixiang ^a,b   Zhu, Huaiping ^a,b   Feng, Dingqing ^a,b   Zhao, Weidong ^a,b   Ling, Bin ^a,b   Wei, Haiming ^c   Tian, Zhigang ^c  

^a Anhui Province Key Laboratory of Molecular Medicine   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

HER 2; Nature killer cells; Ovarian carcinoma; Small interfering RNA

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LACTATE DEHYDROGENASE; SMALL INTERFERING RNA; ERBB2 PROTEIN, HUMAN; ERBB2 PROTEIN, MOUSE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL BASED GENE THERAPY; CELL GROWTH; CONTROLLED STUDY; CYTOLYSIS; EXPRESSION VECTOR; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE REPRESSION; GENE SILENCING; GENE TARGETING; GENETIC TRANSFECTION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NATURAL KILLER CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TARGET CELL; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; GENE EXPRESSION REGULATION; GENE VECTOR; HUMAN; METABOLISM; NUDE MOUSE; OVARY TUMOR; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VECTORS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; RECEPTOR, ERBB-2; RNA, SMALL INTERFERING;

EID: 59249096690     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000162     Document Type: Article

References (30)

1. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989.
2. Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137, 2001.
3. Yang G, Cai KQ, Thompson-Lanza JA, Bast RC Jr and Liu J: Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression. J Biol Chem 279: 4339-4345, 2004.
4. Skirnisdottir I, Sorbe B and Seidal T: The growth factor receptors HER-2/ neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma. Int J Gynecol Cancer 11: 119-129, 2001.
5. Gong JH, Maki G and Klingemann HG: Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8: 652-658, 1994.
6. Igarashi T, Wynberg J, Srinivasan R, Becknell B, McCoy JP Jr, Takahashi Y, et al: Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood 104: 170-177, 2004.
7. Yan Y, Steinherz P, Klingemann HG, Dennig D, Childs BH, McGuirk J, et al: Antileukemia activity of a natural killer cell line against human leukemias. Clin Cancer Res 4: 2859-2868, 1998.
8. Son YI, Dallal RM, Mailliard RB, Egawa S, Jonak ZL and Lotze MT: Interleukin-18 (IL-18) synergizes with IL-2 to enhance cytotoxicity, interferon-gamma production, and expansion of natural killer cells. Cancer Res 61: 884-888, 2001.
9. Sun R, Li AL, Wei HM and Tian ZG: Expression of prolactin receptor and response to prolactin stimulation of human NK cell lines. Cell Res 14: 67-73, 2004.
10. Uharek L, Zeis M, Glass B, Steinmann J, Dreger P, Gassmann W, et al: High lytic activity against human leukemia cells after activation of allogeneic NK cells by IL-12 and IL-2. Leukemia 10: 1758-1764, 1996.
11. Zhang J, Sun R, Wei H, Zhang J and Tian Z: Characterization of interleukin-15 gene-modified human natural killer cells: implications for adoptive cellular immunotherapy. Haematologica 89: 338-347, 2004.
12. Romanski A, Bug G, Becker S, Kampfmann M, Seifried E, Hoelzer D, et al: Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia. Exp Hematol 33: 344-352, 2005.
13. Daldrup-Link HE, Meier R, Rudelius M, Piontek G, Piert M, Metz S, et al: In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging. Eur Radiol 15: 4-13, 2005.
14. Ochsenbein AF, Sierro S, Odermatt B, Pericin M, Karrer U, Hermans J, et al: Roles of tumor localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411: 1058-1064, 2001.
15. Menard S, Pupa SM, Campiglio M and Tagliabue E: Biologic and therapeutic role of HER2 in cancer. Oncogene 22: 6570-6578, 2003.
16. Camilleri-Broet S, Hardy-Bessard AC, Le Tourneau A, Paraiso D, Levrel O, Leduc B, et al: HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group. Ann Oncol 15: 104-112, 2004.
17. Carson WE, Parihar R, Lindemann MJ, Personeni N, Dierksheide J, Meropol NJ, et al: Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur J Immunol 31: 3016-3025, 2001.
18. Pusztai L and Esteva FJ. Continued use of trastuzumab (herceptin) after progression on prior trastuzumab therapy in HER-2-positive metastatic breast cancer. Cancer Invest 24: 187-191, 2006.
19. Ross JS and Gray GS: Targeted therapy for cancer: the HER-2/neu and Herceptin story. Clin Leadersh Manag Rev 17: 333-340, 2003.
20. Tam YK, Miyagawa B, Ho VC and Klingemann HG: Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. J Hematother 8: 281-290, 1999.
21. Tonn T, Becker S, Esser R, Schwabe D and Seifried E: Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematother Stem Cell Res 10: 535-544, 2001.
22. Burshtyn DN, Scharenberg AM, Wagtmann N, Rajagopalan S, Berrada K, Yi T, et al: Recruitment of tyrosine phosphatase HCP by the killer cell inhibitor receptor. Immunity 4: 77-85, 1996.
23. Maki G, Tam YK, Berkahn L and Klingemann HG: Ex vivo purging with NK-92 prior to autografting for chronic myelogenous leukemia. Bone Marrow Transplant 31: 1119-1125, 2003.
24. Klingemann HG, Wong E and Maki G: A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood. Biol Blood Marrow Transplant 2: 68-75, 1996.
25. Suck G: Novel approaches using natural killer cells in cancer therapy. Semin Cancer Biol 16: 412-418, 2006.
26. Uherek C, Tonn T, Uherek B, Becker S, Schnierle B, Klingemann HG, et al: Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood 100: 1265-1273, 2002.
27. Demirtzoglou FJ, Papadopoulos S and Zografos G: Cytolytic and cytotoxic activity of a human natural killer cell line genetically modified to specifically recognize HER-2/neu overexpressing tumor cells. Immunopharmacol Immunotoxicol 28: 571-590, 2006.
28. Chen G, Ling B, Zhu HP, Zhao WD, Wang QH, Zhang HY, et al: Effect of natural killer cell line NK-92 against human ovarian carcinoma cells in vitro and in vivo. Zhonghua Fu Chan Ke Za Zhi 40: 476-479, 2005.
29. Shahied LS, Tang Y, Alpaugh RK, Somer R, Greenspon D and Weiner LM: Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. J Biol Chem 279: 53907-53914, 2004.
30. Wiltschke C, Tyl E, Speiser P, Steininger A, Zeillinger R, Kury F, et al: Increased natural killer cell activity correlates with low or negative expression of the HER-2/neu oncogene in patients with breast cancer. Cancer 73: 135-139, 1994.